Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $219.30 USD
Change Today +0.43 / 0.20%
Volume 707.4K
ILMN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILMN) Snapshot

Open
$218.92
Previous Close
$218.87
Day High
$220.86
Day Low
$218.11
52 Week High
07/20/15 - $242.37
52 Week Low
10/15/14 - $145.12
Market Cap
31.7B
Average Volume 10 Days
2.1M
EPS TTM
$3.01
Shares Outstanding
144.7M
EX-Date
--
P/E TM
72.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for ILLUMINA INC (ILMN)

illumina inc (ILMN) Details

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms consist of HiScan and iScan systems, as well as NextSeq 550 system that are array scanners for DNA and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis. It also offers various library preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping, noninvasive prenatal test, and whole-genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. It has a collaboration agreement with Merck Serono to develop a sequencing-based oncology diagnostic. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

3,700 Employees
Last Reported Date: 02/18/15
Founded in 1998

illumina inc (ILMN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $859.2K
President and Director
Total Annual Compensation: $689.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $463.3K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $467.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $403.7K
Compensation as of Fiscal Year 2014.

illumina inc (ILMN) Key Developments

Lockheed Martin, Cisco, Cloudera, Illumina, Intel and Montgomery College Announce Formation of New Healthcare Technology Alliance

Lockheed Martin announced the formation of a new healthcare technology alliance, combining the expertise of leading health IT providers, medical technology companies, and academic institutions to advance public health. The Lockheed Martin Healthcare Technology Alliance's founding members include: Cisco, Cloudera, Illumina, Intel and Montgomery College. Through collaboration between health IT industry and academic partners, this team will develop and refine technologies that will help guide decisions for care, diagnosis and treatment of disease while protecting critical health information. The members of the Lockheed Martin Healthcare Technology Alliance will collaborate on technology solutions that help improve care in rapidly evolving and growing areas of health technology such as those that: secure patient medical information; leverage advances in genomic research; and apply big data solutions to improve public health.

Illumina Inc. Reports Earnings Results for the Second Quarter of 2015; Provides Earnings Guidance for the Full Year 2015

Illumina Inc. reported earnings results for the second quarter of 2015. For the quarter, the company reported revenue increased 21% year-over-year to $539 million, slightly above the guidance provided on last quarter's earnings call. The leverage the company delivered this quarter was also remarkable as non-GAAP earnings per share grew 40% compared to the second quarter of 2014. These robust results were due to strength in sequencing revenue and solid operational execution. Second quarter total sequencing revenues grew 28% year-over-year, driven by record consumables and strength in services. Non-GAAP net income was $120 million for second quarter, and non-GAAP EPS was $0.80. This compares to non-GAAP net income and EPS of $85 million and $0.57, respectively, in the second quarter of 2014. The impact of foreign exchange lowered second quarter non-GAAP EPS by approximately $0.06 relative to last year. The company reported GAAP net income of $102 million or $0.69 per diluted share in the second quarter compared to net income of $47 million or $0.31 per diluted share in the prior year period. Cash flow from operations equaled $171 million. Capital expenditures in second quarter were $41 million, due to spending associated with ERP implementation as well as other ongoing investments focused on scaling the organization, resulting in $130 million of free cash flow. For the year 2015, the company continues to project approximately 20% total company revenue growth and 23% growth on a constant currency basis based on current exchange rates. The company has increased 2015 non-GAAP EPS projections to $3.39 to $3.45, up from $3.36 to $3.42. Additionally, the company continues to project a full year pro forma tax rate of 27%, which assumes 2015 federal R&D tax credit and other tax extenders are passed prior to fiscal year-end. Forecasts are for sales of $2.26422 billion and non-GAAP EPS of $3.44.

Illumina Inc. Names Sanjay Chikarmane as Senior Vice President and General Manager of Enterprise Informatics

Illumina Inc. announced that Sanjay Chikarmane has been named Senior Vice President and General Manager of Illumina's Enterprise Informatics business. Chikarmane will lead the development and commercialization of products and services aimed at turning genomic data into actionable information for researchers and clinicians. He will report to Illumina President, Francis deSouza. Chikarmane joins Illumina with more than 20 years of experience in enterprise software at companies including HP, BEA Systems and most recently, SAP.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILMN:US $219.30 USD +0.43

ILMN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Avago Technologies Ltd $125.14 USD -2.51
Dr Reddy's Laboratories Ltd 4,076 INR +163.00
Hologic Inc $41.66 USD +0.91
Sigma-Aldrich Corp $139.61 USD -0.06
Waters Corp $133.49 USD +0.90
View Industry Companies
 

Industry Analysis

ILMN

Industry Average

Valuation ILMN Industry Range
Price/Earnings 66.9x
Price/Sales 15.2x
Price/Book 17.6x
Price/Cash Flow 59.7x
TEV/Sales 13.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.